Securities Registration: Employee Benefit Plan (s-8)
24 Août 2018 - 11:04PM
Edgar (US Regulatory)
As filed with the Securities and Exchange
Commission on August 24, 2018
Registration No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF 1933
RXi PHARMACEUTICALS
CORPORATION
(Exact name of registrant as specified in
its charter)
|
|
|
|
|
Delaware
|
|
|
|
45-3215903
|
(State or other jurisdiction of
incorporation or organization)
|
|
|
|
(I.R.S. Employer
Identification Number)
|
257 Simarano Drive, Suite 101
Marlborough, Massachusetts 01752
(508) 767-3861
(Address, including zip code, and telephone
number, including area code, of registrant’s principal executive offices)
RXi Pharmaceuticals Corporation 2012
Long Term Incentive Plan
RXi Pharmaceuticals Corporation Employee
Stock Purchase Plan
(Full Title of the Plan)
Geert Cauwenbergh, Dr. Med. Sc.
President
RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough, Massachusetts 01752
(508) 767-3861
(Name, address, including zip code, and
telephone number, including area code, of agent for service)
Copies to:
|
Ryan A. Murr
Gibson, Dunn & Crutcher LLP
555 Mission Street, Suite 3000
San Francisco, CA 94105
Telephone: (415) 393-8373
Facsimile: (415) 374-8430
|
Approximate date of commencement of proposed
sale to the public:
From time to time after this registration
statement becomes effective, as determined by the selling stockholders.
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging
growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☐
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
☒
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☐
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 7(a)(2)(B) of the Securities Act.
☐
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of each class of
securities to be registered
|
|
Amount
to be
registered (1)
|
|
Proposed
maximum
offering price
per share (2)
|
|
Proposed
maximum
aggregate
offering Price (2)
|
|
Amount of
registration fee
|
Common Stock, par value $0.0001 per share (“Common Stock”), to be issued under the RXi Pharmaceuticals Corporation 2012 Long Term Incentive Plan
|
|
625,000
|
|
$1.495
|
|
$934,375.00
|
|
$116.33
|
Common Stock to be issued under the RXi Pharmaceuticals Corporation Employee Stock Purchase Plan
|
|
400,000
|
|
$1.495
|
|
598,000.00
|
|
74.45
|
Total
|
|
1,025,000
|
|
|
|
$1,532,375.00
|
|
$190.78
|
|
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement also covers such additional shares of Common Stock as may be issued under the RXi Pharmaceuticals Corporation 2012 Long Term Incentive Plan (the “
2012 LTIP
”) and the RXi Pharmaceuticals Employee Stock Purchase Plan (the “
ESPP
”) to prevent dilution from stock splits, stock dividends and similar transactions.
|
(2)
|
Calculated pursuant to Rule 457(h) of the Securities Act of 1933,
as amended, solely for the purpose of computing the amount of the registration fee, on the basis of the average of the high and
low prices of the registrant’s Common Stock quoted on The Nasdaq Capital Market on August 20, 2018.
|
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
PURSUANT TO GENERAL INSTRUCTION E OF FORM S-8
This Registration Statement has been filed
by RXi Pharmaceuticals Corporation (the “
Registrant
”) to register 625,000 additional shares of Common Stock
to be offered pursuant to the 2012 LTIP. Pursuant to Instruction E to Form S-8, the Registrant incorporates by reference the Registration
Statements on Form S-8 filed with the Securities and Exchange Commission on August 30, 2012 (File No. 333-183633), June 21, 2013
(File No. 333-189522) and February 2, 2017 (File No. 333-215870), together with all exhibits filed therewith or incorporated herein
by reference.
This
Registration Statement has been filed by the Registrant to register 400,000 additional shares of Common Stock to be offered pursuant
to the ESPP. Pursuant to Instruction E to Form S-8, the Registrant incorporates by reference the Registration Statements on Form
S-8 filed on June 21, 2013 (File No. 333-189521) and February 2, 2017 (File No. 333-215871) filed with the Securities and Exchange
Commission, together with all exhibits filed therewith or incorporated herein by reference.
*
Filed herewith.
Signatures
Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements
for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in Marlborough, Massachusetts, on August 24, 2018.
|
RXi PHARMACEUTICALS CORPORATION
|
|
|
|
By:
|
/s/ Geert Cauwenbergh
|
|
|
Geert Cauwenbergh, Dr. Med. Sc.
|
|
|
President, Chief Executive Officer and acting Chief Financial Officer
|
Power of Attorney
KNOW ALL PERSONS BY THESE PRESENTS, that
each person whose signature appears below constitutes and appoints Geert Cauwenbergh, Dr. Med. Sc. as attorney-in-fact and
agent, with full power of substitution and resubstitution, in any and all capacities, to sign any and all amendments (including
post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents
in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, with full
power to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done
in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming
all that said attorney-in-fact and agent, or his substitute or substitutes, may do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
/s/ Geert
Cauwenbergh
Geert Cauwenbergh, Dr. Med. Sc.
|
|
President, Chief Executive
Officer,
Acting
Chief Financial Officer and Director
(Principal
Executive Officer and
Principal Financial Officer)
|
|
August 24, 2018
|
|
|
|
/s/ Caitlin
Kontulis
Caitlin Kontulis
|
|
Senior Director of Finance and Secretary
(Principal Accounting Officer)
|
|
August 24, 2018
|
|
|
|
/s/ Robert
J. Bitterman
Robert J. Bitterman
|
|
Director
|
|
August 24, 2018
|
|
|
|
/s/ Keith
L. Brownlie
Keith L. Brownlie
|
|
Director
|
|
August 24, 2018
|
|
|
|
/s/ H.
Paul Dorman
H. Paul Dorman
|
|
Director
|
|
August 24, 2018
|
|
|
|
/s/ Jonathan
E. Freeman
Jonathan E. Freeman, Ph.D.
|
|
Director
|
|
August 24, 2018
|
|
|
|
/s/ Curtis
A. Lockshin
Curtis A. Lockshin, Ph.D.
|
|
Director
|
|
August 24, 2018
|
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024